Number of EFPIA and PhRMA member and non-member companies in the top 50 biopharmaceutical companies as ranked by 2015 worldwide prescription sales and their public commitment to disclosing clinical trial data
| Top 50 companies: membership of EFPIA and/or PhRMA | General data sharing statement, n (%) | EFPIA/PhRMA principles | Five EFPIA/PhRMA joint principles of responsible clinical data sharing | ||||||
| Commitment to sharing clinical trial data with researchers | Public availability of CSR synopsis as a minimum | Availability of results for trial participants | Public certification of adoption of EFPIA/PhRMA commitments | Commitment to publish clinical trial data (phase III minimum) | All five principles | ||||
| Member (n=30) | 26 (86.7) | 20 (66.7) | 25 (83.3) | 22 (73.3) | 18 (60.0) | 21 (70.0) | 24 (80.0) | 16 (53.3) | |
| Non-member (n=20) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Total (n=50) | 26 (52.0) | 20 (40.0) | 25 (50.0) | 23 (46.0) | 18 (36.0) | 21 (42.0) | 24 (48.0) | 16 (32.0) | |
CSR, clinical study report; EFPIA, European Federation of Pharmaceutical Industries and Associations; PhRMA, Pharmaceutical Research and Manufacturers of America.